text.skipToContent text.skipToNavigation

AdnaTest ProstateCancer CE

For the enrichment and molecular characterization of circulating tumor cells (CTCs) from the blood of prostate cancer patients for gene expression analysis
  • Compliance with EU IVD Directive 98/79/EC
  • Efficient isolation and detection of CTCs from whole blood
  • Molecular characterization of CTCs
  • High specificity and sensitivity
  • Processing of multiple samples in parallel
AdnaTest ProstateCancer allows molecular characterization of CTCs by combining AdnaTest ProstateCancerSelect with AdnaTest ProstateCancerDetect using the Combination of Combinations Principle (COCP). AdnaTest ProstateCancerSelect is a highly specific immunomagnetic cell-selection system for enriching circulating tumor cells from peripheral blood. AdnaTest ProstateCancerDetect allows sensitive analysis of prostate cancer-associated gene expression in immunomagnetically enriched tumor cells by reverse transcription and PCR.

Buy Products

Cat No./ID: 395432
AdnaTest ProstateCancerSelect CE
Order Product
For isolation of CTCs and the subsequent extraction of mRNA from human whole blood for 12 preparations
Cat No./ID: 396432
AdnaTest ProstateCancerDetect CE
Order Product
RT-PCR kit for detection of prostate cancer-associated gene expression in enriched tumor cells
Cat No./ID: 399911
Order Product
For 8 tubes, 1.5 ml
Cat No./ID: 399921
Order Product
For 8 tubes, 15 ml

The AdnaTest ProstateCancer CE is intended for in vitro diagnostic use.

Product Details

AdnaTest ProstateCancer is a highly specific immunomagnetic cell selection system for enriching circulating tumor cells from peripheral blood and includes a highly sensitive RT-PCR for detecting prostate cancer-specific mRNA markers.
AdnaTest technology uses an optimized combination of antibodies for cell selection in 5 ml whole blood and a combination of tumor-associated markers for the detection of tumor cells: PSMA, PSA and EGFR.
The AdnaTest uses a two-step process (Select and Detect) to generate results within 5 hours (see figures “AdnaTest workflow”). AdnaTest ProstateCancerSelect enables the immunomagnetic enrichment of tumor cells from whole blood via epithelial- and tumor-associated antigens. Antibodies against epithelial- and tumor-associated antigens are conjugated to magnetic beads for labeling of tumor cells. Labeled cells are extracted by a magnetic particle concentrator (AdnaMag-L and AdnaMag-S), lysed and mRNA is then purified from these lysates (see figures “AdnaTest Select – Immunomagnetic cell selection with multiple tumor-associated antibodies labeled to magnetic beads”). In the second step, the isolated mRNA is transcribed into cDNA and can be amplified using multiplex PCR (see figures “AdnaTest Detect – Multiplex PCR of various cancer-associated tumor markers”). AdnaTest ProstateCancerDetect contains Oligo (dT) 25-coated beads for the isolation of mRNA from the lysate of pre-enriched tumor cells. Reverse transcription results in cDNA that can subsequently be used as template for tumor cell detection and characterization by multiplex PCR. Multiplex PCR provides tumor-associated gene expression profiles for a variety of relevant tumor markers to ensure that the selected cells are cancer cells. The PrimerMix ProstateDetect allows the amplification of three tumor associated antigens and one control gene. With the PrimerMix AR-Detect the androgen receptor (AR) is amplified. The primers generate fragments of the following sizes:
PrimerMix ProstateDetect
 Target gene  PCR fragment size (bp)
 PSMA  449
 PSA  357
 EGFR  163
 Actin (internal PCR control)  120
PrimerMix AR-Detect
 Target gene  PCR fragment size (bp)
 AR  440

  • Isolation of CTCs from whole human blood
  • Molecular characterization of CTCs  
  • mRNA profiling
  • Liquid biopsy

Product Resources

fragment fix placeholder

Customers who bought these products also bought